Harrow (HROW) Total Debt Growth (3y) (2014 - 2026)
Harrow (HROW) Total Debt Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 15.43% |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | -7.08% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 11.33% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -3.67% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -10.43% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | -13.72% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 92.83% |
| 10 | Harrow | 1.53 Bn | 1.45 Bn | 50.36 Mn | 19.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19.88% |
| Mar 31, 2026 | 20.04% |
| Dec 31, 2025 | 32.66% |
| Sep 30, 2025 | 49.81% |
| Jun 30, 2025 | -18.86% |
| Mar 31, 2025 | 16.12% |
| Dec 31, 2024 | 45.24% |
| Sep 30, 2024 | 46.15% |
| Jun 30, 2024 | 37.44% |
| Mar 31, 2024 | 155.85% |
| Dec 31, 2023 | 138.88% |
| Sep 30, 2023 | 133.57% |
| Jun 30, 2023 | 109.81% |
| Mar 31, 2023 | 144.13% |
| Dec 31, 2022 | 104.29% |
| Sep 30, 2022 | 77.74% |
| Jun 30, 2022 | 74.76% |
| Mar 31, 2022 | 82.07% |
| Dec 31, 2021 | 77.94% |
| Sep 30, 2021 | 78.01% |